Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

The discovery of RET fusions in lung cancers has uncovered a new therapeutic target for patients whose tumors harbor these changes. In an unselected population of non–small cell lung carcinomas (NSCLCs), RET fusions are present in 1% to 2% of cases. This incidence increases substantially, however, i...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Drilon, Alexander, Wang, Lu, Hasanovic, Adnan, Suehara, Yoshiyuki, Lipson, Doron, Stephens, Phil, Ross, Jeffrey, Miller, Vincent, Ginsberg, Michelle, Zakowski, Maureen F., Kris, Mark G., Ladanyi, Marc, Rizvi, Naiyer
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4160032/
https://ncbi.nlm.nih.gov/pubmed/23533264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0035
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak